 |
|
|
|
|
|
Treatment
|
|
Location |
|
Last Updated |
|
|
|
Details |
|
A Phase II Trial of Bevacizumab (avastin) and Irinotecan (CPT-11) for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment With Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (Bevacizumab Alone for Recurrent Gliomas)
|
|
Bethesda, MD |
|
04/21/2009 |
|
|
|
|
|
Details |
|
A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas |
|
San Francisco, CA |
|
04/06/2009 |
|
|
|
Details |
|
Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
|
|
San Francisco, CA
Washington, DC
Chicago, IL
Boston, MA
Bethesda, MD
Durham, NC
Philadelphia, PA
Pittsburgh, PA
Memphis, TN
Seattle, WA |
|
11/08/2008 |
|
|
|
|
|
Details |
|
A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme
|
|
Houston, TX |
|
10/27/2008 |
|
|
|
Details |
|
A Phase II Trial With Bevacizumab (Avastin) and Irinotecan (CPT-11) for Patients With Primary Brain Tumors and Progression After Standard Therapy |
|
Copenhagen, Denmark |
|
08/18/2007 |
|
|
|
|
|
Details |
|
Combination Therapy With Thalidomide and CPT-11 in Patients With Recurrent Anaplastic Gliomas or Glioblastoma Multiforme |
|
Houston , TX |
|
04/15/2007 |
|
|
|
Details |
|
Phase I/II Study of High Dose Irinotecan (Camptosar, CPT-11) in Patients With Recurrent Unresectable Malignant Glioma on Steroids/Anti-Epileptics |
|
Louisville, KY |
|
05/29/2006 |
|
|
|
|
|
Details |
|
A Phase I Trial Using Combination Irinotecan (CPT-11) and Thalidomide for Recurrent CNS Tumors |
|
Albuquerque, NM |
|
05/02/2006 |
|
|
|
Details |
|
Phase I trial of Temodar plus O6-Benzylguanine plus Irinotecan (CPT-11) in the treatment of patients with recurrent/progressive Cerebral anaplastic gliomas. |
|
Durham, NC |
|
12/03/2005 |
|
|
|
|
|
Details |
|
ZD1839 and Oral Irinotecan in Treating Young Patients with Refractory Solid Tumors |
|
Memphis, TN |
|
12/03/2005 |
|
|
|
Details |
|
Evaluation of CPT-11 (Irinotecan) in chemonaive patients with inoperable brain metastases from non-small cell lung cancer |
|
Bennington, VT |
|
11/21/2005 |
|
|
|
|
|
Details |
|
Phase II treatment with Irinotecan (CPT-11) plus Celebrex® of adults with primary malignant glioma. |
|
Durham, NC |
|
11/20/2005 |
|
|
|
Details |
|
Phase I treatment with Irinotecan (CPT-11) plus Temozolomide (Temodar) of children with primary recurrent malignant brain tumors. |
|
Durham, NC |
|
11/13/2005 |
|
|
|
|
|
Details |
|
Pilot study of Irinotecan (CPT-11) given concurrently with 76 Gy of conformal multiple fraction per day External Beam Radiotherapy followed by Maintenance Therapy with BCNU plus Irinotecan (CPT-11) for newly diagnosed diffuse pontine glioma. |
|
Durham, NC |
|
11/13/2005 |
|
|
|
